Lexeo Therapeutics Inc. C... (LXEO)
NASDAQ: LXEO
· Real-Time Price · USD
3.22
-1.23 (-27.64%)
At close: May 06, 2025, 3:59 PM
3.09
-4.03%
After-hours: May 06, 2025, 07:58 PM EDT
-27.64% (1D)
| Bid | 3.09 |
| Market Cap | 106.89M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -98.33M |
| EPS (ttm) | -3.09 |
| PE Ratio (ttm) | -1.04 |
| Forward PE | -1.5 |
| Analyst | Buy |
| Ask | 3.3 |
| Volume | 1,659,153 |
| Avg. Volume (20D) | 846,746 |
| Open | 4.37 |
| Previous Close | 4.45 |
| Day's Range | 3.20 - 4.55 |
| 52-Week Range | 1.45 - 19.50 |
| Beta | 1.28 |
About LXEO
Lexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associat...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 3, 2023
Employees 72
Stock Exchange NASDAQ
Ticker Symbol LXEO
Website https://www.lexeotx.com
Analyst Forecast
According to 5 analyst ratings, the average rating for LXEO stock is "Buy." The 12-month stock price forecast is $21, which is an increase of 552.19% from the latest price.
Stock Forecasts1 month ago
+50.92%
Lexeo Therapeutics shares are trading higher after...
Unlock content with
Pro Subscription
5 months ago
-0.65%
Lexeo Therapeutics shares are trading higher. Leerink Partners maintained an Outperform rating on the stock.
